Saccharomyces Boulardii: The Yeast Probiotic, Evidence-Reviewed
⚡ 60-Second Summary
Saccharomyces boulardii is a non-pathogenic yeast used as a probiotic. Because it's a fungus, antibacterial antibiotics don't kill it — making it the probiotic of choice during antibiotic therapy. The strain with virtually all the evidence is S. boulardii CNCM I-745 (sold as Florastor in the U.S., Perenterol in Europe).
Strongest evidence: antibiotic-associated diarrhea (AAD), recurrent Clostridioides difficile, traveler's diarrhea, pediatric acute infectious diarrhea.
Typical dose: 250-500 mg twice daily (≈5-10 billion CFU/day), starting within 48 hours of the first antibiotic dose and continuing 1-2 weeks afterward.
What is Saccharomyces boulardii?
Saccharomyces boulardii is a tropical yeast first isolated in 1923 by French microbiologist Henri Boulard from lychee and mangosteen fruit in Indochina, while he was investigating why local people drinking a fruit-skin tea seemed protected from cholera-related diarrhea. Genomically, it is a strain of Saccharomyces cerevisiae (baker's/brewer's yeast), but its physiology — heat tolerance up to 37°C, acid resistance, lack of pathogenicity — is distinct enough that it is treated separately in clinical practice.
Two key features set it apart from all bacterial probiotics:
- Antibiotic resistant — no antibacterial drug affects it
- Transient colonizer — it does not take up residence in the colon, so it is cleared within 3-5 days of stopping it; that's a feature for safety, not a bug
How S. boulardii works in the gut
Multiple complementary mechanisms have been characterized:
- Toxin neutralization: S. boulardii secretes a 54-kDa serine protease that cleaves C. difficile toxins A and B and their receptors on enterocytes
- Pathogen binding: mannan polymers on the yeast cell wall bind enteropathogens (E. coli, Salmonella) and carry them out in stool
- Brush-border enzyme support: increases sucrase, lactase, and maltase activity — relevant to post-infectious malabsorption
- Anti-inflammatory: downregulates NF-κB and IL-8 signaling in enterocytes
- SCFA & polyamine output: raises spermidine and short-chain fatty acid levels in the lumen
Evidence-based benefits of S. boulardii
1. Antibiotic-associated diarrhea (AAD)
The 2017 Cochrane review for probiotics in adult AAD (Goldenberg et al.) and a 2015 McFarland meta-analysis specifically of S. boulardii (21 RCTs, 4,780 patients) both found AAD risk roughly halved (RR ~0.47) with S. boulardii vs placebo. Effective dose: 500 mg/day, started within 48 hours of antibiotic initiation, continued ≥7 days after antibiotics stop.
2. Recurrent Clostridioides difficile infection
For preventing CDI recurrence — a notoriously difficult outcome to move — S. boulardii at 1 g/day added to vancomycin reduced recurrence from 50% to 17% in McFarland's seminal 1994 trial, and meta-analyses (2017) confirm roughly 50% recurrence reduction. The IDSA 2017 CDI guideline acknowledges adjunctive probiotic use without a strong recommendation; clinicians often add S. boulardii during the antibiotic course and for 4 weeks afterward.
3. Traveler's diarrhea
A 2007 meta-analysis (McFarland, Travel Med Infect Dis) of 12 RCTs showed S. boulardii at 250-1000 mg/day starting 5 days before travel reduced traveler's-diarrhea incidence by ~15% (number needed to treat ≈10). Effect size is modest but consistent.
4. Acute infectious diarrhea in children
ESPGHAN guidelines endorse S. boulardii (250-750 mg/day for 5-7 days) as adjunctive therapy to oral rehydration for acute pediatric gastroenteritis. Trials show ~24-hour reduction in diarrhea duration.
5. Inflammatory bowel disease (preliminary)
Small RCTs in maintenance of remission for ulcerative colitis (1 g/day add-on to mesalamine) showed reduced relapse rates, but trials are small and short. Not a substitute for established IBD therapy. Evidence is weaker for Crohn's disease.
6. H. pylori adjunct
Adding 1 g/day S. boulardii to triple therapy reduces antibiotic-associated GI side effects and modestly improves eradication rates; this use is well-established in pediatric guidelines.
S. boulardii forms compared
| Form | Best for | Typical dose | Notes |
|---|---|---|---|
| Lyophilized capsule (CNCM I-745, "Florastor") | AAD, CDI, traveler's diarrhea | 250-500 mg BID | Shelf-stable. The form used in essentially all positive clinical trials. |
| Sachet/powder | Pediatric use, NG tube administration | 250-500 mg BID | Mix in cool food or water; do not exceed 50°C. |
| Generic "S. boulardii" without strain code | Not recommended for clinical use | Variable | Strain identity and viability cannot be assumed equivalent to CNCM I-745. |
| Multi-strain blends | General gut support | Per label | S. boulardii dose may be sub-clinical when blended with other strains. |
For comparison with bacterial probiotics during antibiotic therapy, see Lactobacillus probiotics.
How much S. boulardii should you take?
- AAD prevention (adults): 250-500 mg twice daily, started within 48h of first antibiotic, continued 1-2 weeks afterward
- CDI recurrence prevention: 500 mg twice daily (1 g/day) during and for 4 weeks after antibiotic therapy
- Traveler's diarrhea: 250-500 mg/day, starting 5 days before travel, continued throughout
- Pediatric acute diarrhea: 250-500 mg/day for children >1 year, lower for infants — always under pediatrician guidance
500 mg of lyophilized S. boulardii corresponds to ~5 billion CFU. Time to clinical effect for AAD prevention is essentially the same day; for CDI prevention, the protective effect builds over the antibiotic course.
Safety, side effects, and immunocompromised hosts
For healthy adults and children, S. boulardii has a strong safety profile across hundreds of trials and decades of European use. Common short-term effects:
- Mild bloating, gas, or thirst (rare)
- Constipation in a minority
Fungemia warning — critically ill and central-line patients
Saccharomyces fungemia has been reported in roughly 50 published cases, virtually all in ICU patients with central venous catheters, severe immunosuppression, or compromised gut barriers. The U.S. and European labels explicitly warn against use in:
- Critically ill or ICU patients
- Central venous catheters
- Severe immunosuppression, neutropenia, transplant recipients
- Premature infants without specialist supervision
Healthcare staff handling capsules for ICU patients have been implicated in environmental contamination of nearby central lines — another reason hospital protocols often restrict its use.
Pregnancy and breastfeeding
Limited but reassuring data; no safety signals in animal reproductive studies or in pregnancy registries. Discuss with your obstetrician.
Drug and nutrient interactions
- Antibacterial antibiotics — no interaction; S. boulardii is unaffected. Take any time relative to antibiotic doses.
- Antifungal drugs (fluconazole, nystatin, amphotericin B) — these will kill S. boulardii. Do not co-administer. Stop S. boulardii before starting an antifungal.
- Immunosuppressants — increased fungemia risk; discuss with prescriber.
- Acid suppression — minimal direct interaction; S. boulardii is acid-resistant.
- MAOIs (theoretical) — historical concern around tyramine in baker's yeast; lyophilized S. boulardii does not contain meaningful tyramine.
Use our interaction checker for additional combinations.
Who might benefit — and who shouldn't bother
| Most likely to benefit | Should avoid or use cautiously |
|---|---|
| Adults starting a course of antibiotics, especially clindamycin or broad-spectrum | ICU patients with central venous catheters |
| Patients with first or recurrent C. difficile (adjunct) | Severe immunosuppression, transplant, neutropenia |
| Travelers to high-risk regions | Anyone on antifungal therapy |
| Children with acute infectious diarrhea (under pediatric guidance) | Premature infants without specialist supervision |
Frequently asked questions
How much Saccharomyces boulardii should I take?
250-500 mg twice daily (5-10 billion CFU/day) of S. boulardii CNCM I-745. For C. difficile, 1 g/day during and 4 weeks after antibiotics.
Can I take S. boulardii with antibiotics?
Yes — that's its main advantage. As a yeast it is unaffected by antibacterial antibiotics. Start within 48h of the first dose. Do not combine with antifungals.
Does S. boulardii help with C. difficile?
It is the only probiotic with reasonably consistent CDI-recurrence evidence — roughly 50% relative risk reduction when added to vancomycin or fidaxomicin.
Is S. boulardii safe for everyone?
For healthy adults and children, yes. Avoid in ICU patients with central lines, severe immunosuppression, transplant, neutropenia, and premature infants without specialist input.
Will S. boulardii cause a yeast infection?
S. boulardii is genetically and clinically distinct from Candida species and does not cause vaginal yeast infections. It can rarely cause fungemia in critically ill or immunocompromised hosts.
How long does S. boulardii stay in the gut?
It is transient — viable yeast is largely cleared within 3-5 days of stopping the supplement. That's why you must take it daily during the at-risk period.
Related ingredients and articles
Lactobacillus
Bacterial probiotics — strain-specific, antibiotic-sensitive.
Bifidobacterium
The other major probiotic genus, often paired with Lactobacillus.
Bacillus coagulans
A spore-forming bacterial alternative for shelf-stable use.
Probiotics with Antibiotics (2026)
How to choose, time, and dose probiotics during antibiotic therapy.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, immunocompromised, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.